Octapharma
Octapharma AG, headquartered in Switzerland (CH), is a leading global player in the biopharmaceutical industry, specialising in the development and production of human proteins derived from human plasma and recombinant technologies. Founded in 1983, Octapharma has established a strong presence in Europe, North America, and Asia, with a commitment to innovation and quality. The company’s core product offerings include a range of immunoglobulins, coagulation factors, and albumin, which are essential for treating various medical conditions, including immune deficiencies and bleeding disorders. Octapharma is renowned for its dedication to patient safety and product efficacy, setting it apart in a competitive market. With a robust pipeline and a focus on research and development, Octapharma has achieved significant milestones, positioning itself as a trusted name in the biopharmaceutical sector, committed to improving patient outcomes worldwide.
DitchCarbon Score
How does Octapharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Octapharma's score of 30 is higher than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Octapharma's reported carbon emissions
In 2023, Octapharma reported total carbon emissions of approximately 177,000 kg CO2e, comprising 102,000 kg CO2e from Scope 1, 4,000 kg CO2e from Scope 2, and 71,000 kg CO2e from Scope 3 emissions. This reflects a slight decrease from 2022, when total emissions were about 181,000 kg CO2e. The company has made significant strides in its climate commitments, achieving a 22% reduction in overall emissions since 2019 and aiming for a further 30% reduction by 2028. Octapharma is committed to achieving Net Zero emissions by 2050, with this long-term goal encompassing all scopes of emissions. The company’s initiatives are not cascaded from any parent organization, indicating a direct commitment to its sustainability targets. The production emission factor for plasma was reported at 1,160 kg CO2e per tonne in 2023, highlighting the environmental impact of its operations. Overall, Octapharma's proactive approach to reducing carbon emissions and its ambitious long-term goals position it as a responsible player in the biopharmaceutical industry, dedicated to mitigating climate change.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Octapharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
